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The clinical course and disease activity of patients with
HTLV-1 associated myelopathy / tropical spastic para-
paresis (HAM/TSP) are different among patients. There-
fore, the treatment plan should be designed based on
these backgrounds of patients. However, there is little
information about the natural history of HAM/TSP and
biomarkers of disease activity that is associated with
prognosis.
As the candidate for biomarkers to evaluate the dis-
ease activity in HAM/TSP, HTLV-1 proviral load in
PBMC, several cytokines and chemokines in serum or
cerebrospinal fluid (CSF) are known to be increased in
HAM/TSP patients. However, little is known which
parameter of these candidates is most associated with
disease severity.
Therefore, we investigated the clinical course of 30
HAM/TSP patients without any history of treatment.
Furthermore, we measured quantitatively the concentra-
tion of a series of cytokines and chemokines in serum
and CSF, and HTLV-1 proviral DNA load in PBMC.
Then, the level of these markers was evaluated for the
correlation with disease severity.
In HAM/TSP patients, the level of CXCL10/IP-10 and
neopterin in CSF was strongly correlated with disease
severity. Interestingly, the level of soluble IL-2 receptor
and CXCL10/IP-10 in serum was also correlated with
disease severity with statistical significance. Furthermore,
based on the clinical course and laboratory findings,
HAM/TSP was classified into 4 different clinical sub-
types as follows; (1) Rapidly progressive (active), (2-A)
Chronic progressive (active), (2-B) Chronic progressive
(inactive), (3) Chronic mild (inactive). This classification
might be useful to determine the therapeutic strategy
for patients with HAM/TSP.
Author details
1Institute of Medical Science, St. Marianna University School of Medicine,
Kawasaki, Japan.
2Department of Hematology, Imamura Bun-in Hospital,
Kagoshima, Japan.
3Molecular Pathology, Center for Chronic Viral Diseases,
Graduate School of Medical and Dental Sciences, Kagoshima University,
Kagoshima, Japan.
4Viral Immunology Section, Neuroimmunology Branch,
National Institute of Health, Bethesda, MD, USA.
Published: 6 June 2011
doi:10.1186/1742-4690-8-S1-A42
Cite this article as: Yamano et al.: Clinical subtype of HAM/TSP based
on clinical course and laboratory findings. Retrovirology 2011 8(Suppl 1):
A42.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
* Correspondence: yyamano@marianna-u.ac.jp
1Institute of Medical Science, St. Marianna University School of Medicine,
Kawasaki, Japan
Full list of author information is available at the end of the article
Yamano et al. Retrovirology 2011, 8(Suppl 1):A42
http://www.retrovirology.com/content/8/S1/A42
© 2011 Yamano et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.